Trial · NCT03160898
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 12 in the Percent Predicted Slow Vital Capacity (SVC) | Placebo | -6.46 | Standard Error 0.964 | percent predicted | |
| Change From Baseline to Week 12 in the Percent Predicted Slow Vital Capacity (SVC) | Reldesemtiv 150 mg Twice Daily | -4.97 | Standard Error 0.952 | percent predicted | |
| Change From Baseline to Week 12 in the Percent Predicted Slow Vital Capacity (SVC) | Reldesemtiv 300 mg Twice Daily | -4.62 | Standard Error 0.963 | percent predicted | |
| Change From Baseline to Week 12 in the Percent Predicted Slow Vital Capacity (SVC) | Reldesemtiv 450 mg Twice Daily | -4.58 | Standard Error 0.927 | percent predicted | |
| Change From Baseline to Week 12 in the Percent Predicted Slow Vital Capacity (SVC) | Reldesemtiv 300 mg & 450 mg | -4.60 | Standard Error 0.701 | percent predicted | |
| Change From Baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R) Total Score | Placebo | -3.53 | Standard Error 0.313 | change in score | |
| Change From Baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R) Total Score | Reldesemtiv 150 mg Twice Daily | -2.40 | Standard Error 0.311 | change in score | |
| Change From Baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R) Total Score | Reldesemtiv 300 mg Twice Daily | -2.62 | Standard Error 0.317 | change in score | |
| Change From Baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R) Total Score | Reldesemtiv 450 mg Twice Daily | -2.94 | Standard Error 0.307 | change in score | |
| Change From Baseline to Week 12 in the ALS Functional Rating Scale - Revised (ALSFRS-R) Total Score | Reldesemtiv 300 mg & 450 mg | -2.78 | Standard Error 0.228 | change in score | |
| Slope of Muscle Strength Mega-score From Baseline to Week 12 | Placebo | -0.1444 | Standard Error 0.02492 | change in mega-score per day | |
| Slope of Muscle Strength Mega-score From Baseline to Week 12 | Reldesemtiv 150 mg Twice Daily | -0.1198 | Standard Error 0.02463 | change in mega-score per day | |
| Slope of Muscle Strength Mega-score From Baseline to Week 12 | Reldesemtiv 300 mg Twice Daily | -0.1299 | Standard Error 0.02474 | change in mega-score per day | |
| Slope of Muscle Strength Mega-score From Baseline to Week 12 | Reldesemtiv 450 mg Twice Daily | -0.0956 | Standard Error 0.02421 | change in mega-score per day | |
| Slope of Muscle Strength Mega-score From Baseline to Week 12 | Reldesemtiv 300 mg & 450 mg | -0.1127 | Standard Error 0.01731 | change in mega-score per day |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03160898/results